These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32663665)

  • 1. Design, synthesis and biological evaluation of novel triaryldimethylaminobutan-2-ol derivatives against Mycobacterium tuberculosis.
    Liu P; Fan S; Wang B; Cao R; Wang X; Li S; Lu Y; Zhong W
    Bioorg Chem; 2020 Sep; 102():104054. PubMed ID: 32663665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
    Chahine EB; Karaoui LR; Mansour H
    Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMC207 becomes bedaquiline, a new anti-TB drug.
    Palomino JC; Martin A
    Future Microbiol; 2013 Sep; 8(9):1071-80. PubMed ID: 24020736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bedaquiline: a new hope to treat multi-drug resistant tuberculosis.
    Patel RV; Riyaz SD; Park SW
    Curr Top Med Chem; 2014; 14(16):1866-74. PubMed ID: 25262806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens.
    Riccardi N; Del Puente F; Magnè F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(1):3-11. PubMed ID: 28625141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Simplification of Bedaquiline: the Discovery of 3-(4-(N,N-Dimethylaminomethyl)phenyl)quinoline-Derived Antitubercular Lead Compounds.
    He C; Preiss L; Wang B; Fu L; Wen H; Zhang X; Cui H; Meier T; Yin D
    ChemMedChem; 2017 Jan; 12(2):106-119. PubMed ID: 27792278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic approaches towards bedaquiline and its derivatives.
    Calvert MB; Furkert DP; Cooper CB; Brimble MA
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127172. PubMed ID: 32291133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis and Biological Evaluation of Anti-tuberculosis Agents based on Bedaquiline Structure.
    Wu C; Luo J; Wu M; Meng F; Cai Z; Chen Y; Sun T
    Med Chem; 2020; 16(5):703-714. PubMed ID: 31203803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATP Synthase, an Emerging Target in TB Drug Discovery: Review of SAR and Clinical Pharmacology of Diarylquinoline Inhibitors.
    Dhulap A; Banerjee P
    Curr Drug Targets; 2021; 22(11):1207-1221. PubMed ID: 33480344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tale of two inhibitors: diarylquinolines and squaramides.
    Chen J; Ekiert DC
    EMBO J; 2023 Aug; 42(15):e114912. PubMed ID: 37435707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TMC207: the first compound of a new class of potent anti-tuberculosis drugs.
    Matteelli A; Carvalho AC; Dooley KE; Kritski A
    Future Microbiol; 2010 Jun; 5(6):849-58. PubMed ID: 20521931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Perspective of ATP Synthase Inhibitors in the Management of the Tuberculosis.
    Divita KM; Khatik GL
    Curr Top Med Chem; 2021; 21(18):1623-1643. PubMed ID: 34517802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug-resistant tuberculosis and culture conversion with bedaquiline.
    Diacon AH; Pym A; Grobusch MP; de los Rios JM; Gotuzzo E; Vasilyeva I; Leimane V; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; De Paepe E; van Heeswijk RP; Dannemann B;
    N Engl J Med; 2014 Aug; 371(8):723-32. PubMed ID: 25140958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.
    Nguyen TV; Cao TB; Akkerman OW; Tiberi S; Vu DH; Alffenaar JW
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1025-37. PubMed ID: 27322153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel.
    Sutherland HS; Tong AST; Choi PJ; Blaser A; Conole D; Franzblau SG; Lotlikar MU; Cooper CB; Upton AM; Denny WA; Palmer BD
    Bioorg Med Chem; 2019 Apr; 27(7):1292-1307. PubMed ID: 30803745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Halting ionic shuttle to disrupt the synthetic machinery-Structural and molecular insights into the inhibitory roles of Bedaquiline towards Mycobacterium tuberculosis ATP synthase in the treatment of tuberculosis.
    Salifu EY; Agoni C; Olotu FA; Dokurugu YM; Soliman MES
    J Cell Biochem; 2019 Sep; 120(9):16108-16119. PubMed ID: 31125144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives.
    Salifu EY; Agoni C; Olotu FA; Soliman MES
    Comput Biol Chem; 2020 Apr; 85():107204. PubMed ID: 31981966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bedaquiline.
    Goulooze SC; Cohen AF; Rissmann R
    Br J Clin Pharmacol; 2015 Aug; 80(2):182-4. PubMed ID: 25702772
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.